Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1955 1
1957 2
1962 2
1968 1
1969 2
1970 2
1971 4
1972 3
1974 2
1975 2
1976 1
1977 4
1978 2
1979 3
1980 3
1981 2
1982 1
1983 1
1984 11
1985 7
1986 4
1987 5
1988 11
1989 11
1990 14
1991 23
1992 13
1993 24
1994 25
1995 31
1996 27
1997 30
1998 29
1999 23
2000 20
2001 32
2002 19
2003 25
2004 34
2005 31
2006 18
2007 16
2008 18
2009 20
2010 17
2011 18
2012 21
2013 29
2014 29
2015 26
2016 29
2017 30
2018 42
2019 42
2020 37
2021 36
2022 39
2023 45
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

930 results

Results by year

Filters applied: . Clear all
Page 1
The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia-lymphoma on behalf of the ATL Working Group of the Japan Society for Transplantation and Cellular Therapy.
Fuji S, Inoue Y, Makiyama J, Nakano N, Ito A, Kawakita T, Eto T, Suehiro Y, Itonaga H, Sawayama Y, Mori Y, Uchida N, Morishima S, Onizuka M, Ishitsuka K, Fukuda T, Atsuta Y, Yoshimitsu M. Fuji S, et al. Among authors: eto t. Bone Marrow Transplant. 2023 Jun;58(6):729-731. doi: 10.1038/s41409-023-01969-7. Epub 2023 Mar 25. Bone Marrow Transplant. 2023. PMID: 36966214 No abstract available.
Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect.
Umino K, Morita K, Ikeda T, Kawaguchi SI, Nagayama T, Ito S, Minakata D, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kimura SI, Kako S, Doki N, Ozawa Y, Mori Y, Eto T, Hiramoto N, Nakamae H, Kanda J, Ichinohe T, Atsuta Y, Nakasone H, Morishima S, Kanda Y. Umino K, et al. Among authors: eto t. Blood. 2023 Sep 14;142(11):1008-1021. doi: 10.1182/blood.2023019799. Blood. 2023. PMID: 37363859
Outcomes in human T-cell leukemia virus type I carriers after hematopoietic stem cell transplantation for diseases other than adult T cell leukemia/lymphoma: a Japanese national survey.
Nakano N, Nakasone H, Fuji S, Shinohara A, Suzuki R, Utsunomiya A, Eto T, Morishima S, Ikegame K, Kakinoki Y, Matsuoka KI, Mori Y, Suehiro Y, Uchida N, Ito A, Doki N, Ozawa Y, Kanda J, Kanda Y, Fukuda T, Atsuta Y, Ogata M. Nakano N, et al. Among authors: eto t. Lancet Reg Health West Pac. 2023 Sep 25;40:100902. doi: 10.1016/j.lanwpc.2023.100902. eCollection 2023 Nov. Lancet Reg Health West Pac. 2023. PMID: 38106528 Free PMC article.
Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation.
Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, Eto T, Nagafuji K, Hiramoto N, Matsuoka KI, Maruyama Y, Ota S, Ishikawa J, Kawakita T, Akasaka T, Kamimura T, Hino M, Fukuda T, Atsuta Y, Yakushijin K. Fuji S, et al. Among authors: eto t. Br J Haematol. 2024 Mar;204(3):959-966. doi: 10.1111/bjh.19228. Epub 2023 Nov 30. Br J Haematol. 2024. PMID: 38037468
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K, Miyoshi H, Yanagida E, Yoshida N, Kiyasu J, Kozai Y, Morikita T, Kato T, Suzushima H, Tamura S, Muta T, Kato K, Eto T, Seki R, Nagafuji K, Sone H, Takizawa J, Seto M, Ohshima K. Kawamoto K, et al. Among authors: eto t. Eur J Haematol. 2017 May;98(5):459-466. doi: 10.1111/ejh.12856. Epub 2017 Mar 3. Eur J Haematol. 2017. PMID: 28129454
Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission.
Yanada M, Yamasaki S, Kondo T, Kawata T, Harada K, Uchida N, Doki N, Yoshihara S, Katayama Y, Eto T, Tanaka M, Takada S, Kawakita T, Nishida T, Ota S, Serizawa K, Onizuka M, Kanda Y, Fukuda T, Atsuta Y, Konuma T. Yanada M, et al. Among authors: eto t. Leukemia. 2024 Mar;38(3):513-520. doi: 10.1038/s41375-023-02119-0. Epub 2023 Dec 21. Leukemia. 2024. PMID: 38129514
Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide.
Shimomura Y, Komukai S, Kitamura T, Sobue T, Akahoshi Y, Kanda J, Ohigashi H, Nakamae H, Hiramoto N, Nagafuji K, Tanaka T, Eto T, Ota S, Maruyama Y, Akasaka T, Matsuoka KI, Mori Y, Fukuda T, Atsuta Y, Terakura S. Shimomura Y, et al. Among authors: eto t. Bone Marrow Transplant. 2024 Jan;59(1):66-75. doi: 10.1038/s41409-023-02142-w. Epub 2023 Oct 28. Bone Marrow Transplant. 2024. PMID: 37898725
Development of an umbilical cord blood transplantation-specific nonrelapse mortality risk assessment score.
Okada Y, Usui Y, Hayashi H, Nishikubo M, Toubai T, Uchida N, Tanaka M, Onizuka M, Takahashi S, Doki N, Uehara Y, Maruyama Y, Ishiwata K, Kawakita T, Sawa M, Eto T, Ishimaru F, Kato K, Fukuda T, Atsuta Y, Kanda J, Yakushijin K, Nakasone H. Okada Y, et al. Among authors: eto t. Blood Adv. 2024 Mar 26;8(6):1359-1368. doi: 10.1182/bloodadvances.2023011837. Blood Adv. 2024. PMID: 38163321 Free PMC article.
IKZF1plus alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial.
Ito Y, Ozawa H, Eto T, Miyamoto T, Kamimura T, Ogawa R, Uchida N, Wake A, Fujisaki T, Ohno Y, Takase K, Okumura H, Takamatsu Y, Kawano N, Akashi K, Nagafuji K. Ito Y, et al. Among authors: eto t. Eur J Haematol. 2023 Jul;111(1):103-112. doi: 10.1111/ejh.13972. Epub 2023 Apr 8. Eur J Haematol. 2023. PMID: 36991564
930 results